Ryan Haumschild, PharmD, MS, MBA, CPEL
Articles by Ryan Haumschild, PharmD, MS, MBA, CPEL
Integrating VMS Treatment Into Comprehensive Women’s Health Management
ByRyan Haumschild, PharmD, MS, MBA, CPEL,JoAnn V. Pinkerton, MD, FACOG, MSCP ,Alexa N. Fiffick, DO, MBS, MSCP ,Kamilia Smith, MD, FACOG, NCMP Panelists discuss how to effectively integrate vasomotor symptom (VMS) treatment into comprehensive health management plans for women, taking into account the significant comorbidities associated with menopause, such as cardiovascular disease and osteoporosis.
Improving Access and Equity in VMS Treatment
ByRyan Haumschild, PharmD, MS, MBA, CPEL,JoAnn V. Pinkerton, MD, FACOG, MSCP ,Alexa N. Fiffick, DO, MBS, MSCP ,Kamilia Smith, MD, FACOG, NCMP Panelists discuss how to improve treatment rates for vasomotor symptoms (VMS) by identifying actionable steps, examining the influence of socioeconomic status on health care access, and proposing initiatives to ensure equitable care for all women experiencing menopause.
Barriers to VMS Treatment and Impact on Long-Term Health
ByRyan Haumschild, PharmD, MS, MBA, CPEL,JoAnn V. Pinkerton, MD, FACOG, MSCP ,Alexa N. Fiffick, DO, MBS, MSCP ,Kamilia Smith, MD, FACOG, NCMP Panelists discuss how underlying factors, including patient resistance to conventional treatments and the stigma surrounding menopause, contribute to the persistent undertreatment of vasomotor symptoms (VMS), which can severely impact women’s quality of life and increase their risk for long-term health issues such as cardiovascular disease and Alzheimer disease.
Understanding the Burden of Menopausal Vasomotor Symptoms
ByRyan Haumschild, PharmD, MS, MBA, CPEL,JoAnn V. Pinkerton, MD, FACOG, MSCP ,Alexa N. Fiffick, DO, MBS, MSCP ,Kamilia Smith, MD, FACOG, NCMP Panelists discuss how innovative neurokinin-targeted therapies for vasomotor symptoms can reshape menopause management and address unmet needs and improving patient outcomes while highlighting the importance of equity in treatment access.
Future Directions of BTK Inhibitors in Leukemia and Lymphoma
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD Experts discuss future directions of BTK inhibitors.
Patient Access Advocacy for BTK Inhibitors
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A panel of specialists discuss patient access advocacy for BTK inhibitors.
Participating Faculty: Perspectives in Bronchiectasis Management
ByNauman Chaudary, MD,Francois Fadell, MD,Bryan Garcia, MD,Ryan Haumschild, PharmD, MS, MBA, CPEL,Margaret M. Johnson, MD,Rebecca C. Keith, MD,Diego J. Maselli, MD,George Solomon, MD,Kevin Winthrop, MD, MPH Clinical Perspectives in Bronchiectasis Management
ByNauman Chaudary, MD,Francois Fadell, MD,Bryan Garcia, MD,Ryan Haumschild, PharmD, MS, MBA, CPEL,Margaret M. Johnson, MD,Rebecca C. Keith, MD,Diego J. Maselli, MD,George Solomon, MD,Kevin Winthrop, MD, MPH